Rhythm Pharmaceuticals (RYTM) Return on Capital Employed (2017 - 2026)
Rhythm Pharmaceuticals' (RYTM) quarterly Return on Capital Employed came in at 55.12% in Q1 2026, up 705.0% year-on-year from 6.85% in Q1 2025, and down 11.27% on a QoQ basis from 49.54% in Q4 2025.
Rhythm Pharmaceuticals (RYTM) Return on Capital Employed (2017 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has 10 years of Return on Capital Employed data on file, last reported at 55.12% in Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 705.0% year-over-year to 55.12% in Q1 2026; TTM through Mar 2026 was 55.12%, a 705.0% increase from a year earlier, with the FY2025 full-year figure at 58.14%, up 4936.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 55.12%, down from 49.54% in the prior quarter.
- Over the last five years, Return on Capital Employed for RYTM reached as high as 49.54% in Q4 2025 and fell as low as 112.49% in Q1 2024.
- Historically, Return on Capital Employed has averaged 71.87% across 5 years, with a median of 64.08% in 2023.
- Across the five-year window, Return on Capital Employed slumped 5621 bps in 2024 and soared 5164 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 51.74% in 2022, then dropped by 24 bps to 63.95% in 2023, then slumped by 58 bps to 101.18% in 2024, then surged by 51 bps to 49.54% in 2025, then declined by 11 bps to 55.12% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 55.12% in Q1 2026, 49.54% in Q4 2025, and 55.5% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Rhythm Pharmaceuticals | 6.98 Bn | 6.64 Bn | 52.96 Mn | -55.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -55.12% |
| Dec 31, 2025 | -49.54% |
| Sep 30, 2025 | -55.50% |
| Jun 30, 2025 | -70.90% |
| Mar 31, 2025 | -62.17% |
| Dec 31, 2024 | -101.18% |
| Sep 30, 2024 | -96.51% |
| Jun 30, 2024 | -100.02% |
| Mar 31, 2024 | -112.49% |
| Dec 31, 2023 | -63.95% |
| Sep 30, 2023 | -65.69% |
| Jun 30, 2023 | -64.08% |
| Mar 31, 2023 | -56.28% |
| Dec 31, 2022 | -51.74% |
| Sep 30, 2022 | -62.57% |
| Jun 30, 2022 | -81.55% |
| Mar 31, 2022 | -72.47% |
| Dec 31, 2021 | -56.83% |
| Sep 30, 2021 | -44.21% |
| Jun 30, 2021 | -37.18% |